Stock Research for REGN

REGN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

REGN Stock Chart & Research Data

The REGN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the REGN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


REGN Due diligence Resources & Stock Charts

The REGN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View REGN Detailed Price Forecast - CNN Money CNN View REGN Detailed Summary - Google Finance
Yahoo View REGN Detailed Summary - Yahoo! Finance Zacks View REGN Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View REGN Trends & Analysis - Trade-Ideas Barrons View REGN Major Holders - Barrons
NASDAQ View REGN Call Transcripts - NASDAQ Seeking View REGN Breaking News & Analysis - Seeking Alpha
Spotlight View REGN Annual Report - CompanySpotlight.com OTC Report View REGN OTC Short Report - OTCShortReport.com
TradeKing View REGN Fundamentals - TradeKing Charts View REGN SEC Filings - Bar Chart
WSJ View Historical Prices for REGN - The WSJ Morningstar View Performance/Total Return for REGN - Morningstar
MarketWatch View the Analyst Estimates for REGN - MarketWatch CNBC View the Earnings History for REGN - CNBC
StockMarketWatch View the REGN Earnings - StockMarketWatch MacroAxis View REGN Buy or Sell Recommendations - MacroAxis
Bullish View the REGN Bullish Patterns - American Bulls Short Pains View REGN Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View REGN Stock Mentions - StockTwits PennyStocks View REGN Stock Mentions - PennyStockTweets
Twitter View REGN Stock Mentions - Twitter Invest Hub View REGN Investment Forum News - Investor Hub
Yahoo View REGN Stock Mentions - Yahoo! Message Board Seeking Alpha View REGN Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for REGN - SECform4.com Insider Cow View Insider Transactions for REGN - Insider Cow
CNBC View REGN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for REGN - OTC Markets
Yahoo View Insider Transactions for REGN - Yahoo! Finance NASDAQ View Institutional Holdings for REGN - NASDAQ


Stock Charts

FinViz View REGN Stock Insight & Charts - FinViz.com StockCharts View REGN Investment Charts - StockCharts.com
BarChart View REGN Stock Overview & Charts - BarChart Trading View View REGN User Generated Charts - Trading View


Latest Financial News for REGN

Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod
Posted on Wednesday June 13, 2018

Key areas of focus in the biotech space include regulatory approvals and licensing/acquisition deals.


See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.
Posted on Friday June 08, 2018

Regeneron Pharmaceuticals Inc NASDAQ/NGS:REGN


Blog Exposure - Regeneron Inks Five-Year Collaboration Deal with Zoetis to Discover Antibody Therapies in Animal Health
Posted on Friday June 08, 2018

LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want access to our free research report on Regeneron Pharma, Inc. (NASDAQ: REGN) ("Regeneron"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=REGN as the Company's latest news hit the wire. On June 06, 2018, the Company announced that it has inked a five-year collaboration deal with Zoetis Inc. (NYSE: ZTS), which is a global animal health Company. The deal is aimed at researching the use of Regeneron's monoclonal antibody therapeutics in animals, and discover new veterinary treatments.


The Bull Case for Regeneron Pharmaceuticals Inc Couldn’t Be More Clear
Posted on Thursday June 07, 2018

After falling from $393 per share early this year to a recent low of $284 per share, analysts have begun pounding the table again for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN). Regeneron is a biotech company known for drugs like Zaltrap, a cancer drug.


Enter a stock symbol to view the stock details.